Inhibition of Nutlin-Resistant HDM2 Mutants by Stapled Peptides

Pharmacological modulation of p53 activity is an attractive therapeutic strategy in cancers with wild-type p53. Presently in clinical trials, the small molecule Nutlin-3A competitively binds to HDM2, a key negative regulator of p53 and blocks its activity. We have described resistance mutations in H...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wei, Siau Jia, Joseph, Thomas, Chee, Sharon, Li, Ling, Yurlova, Larisa, Zolghadr, Kourosh, Brown, Christopher, Lane, David, Verma, Chandra, Ghadessy, Farid
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2013
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3835680/
https://ncbi.nlm.nih.gov/pubmed/24278380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0081068
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars